8-K: Hillenbrand Completes Sale of Majority Stake in Milacron Injection Molding Business to Bain Capital

Hillenbrand finalizes the sale of a majority stake in its Milacron injection molding and extrusion business to Bain Capital for $287 million, focusing on core industrial operations and debt reduction.

Summary

• Hillenbrand has completed the sale of its majority interest in the Milacron injection molding and extrusion business to Bain Capital.
• The sale price was $287 million, subject to closing adjustments.
• Bain Capital now owns approximately 51% of Milacron and has full operational control.
• Hillenbrand retains a 49% ownership stake.
• Hillenbrand expects after-tax net proceeds of approximately $250 million from the sale.
• These proceeds will be used to pay down debt.
• The transaction allows Hillenbrand to focus on its core process and automation equipment business, particularly in the food, pharmaceutical, and polymer end markets.
• Hillenbrand acquired Milacron Holdings Corp. in 2019, which included the injection molding business, Mold-Masters, DME, and Cimcool.
• The Cimcool business was sold in 2020, and Hillenbrand retains ownership of Mold-Masters and DME.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as Hillenbrand completes a strategic divestiture, receives a significant cash infusion, and focuses on core business areas; Bain Capital's involvement also suggests confidence in Milacron's future prospects.

Positives

• Hillenbrand receives $287 million in proceeds, subject to adjustments, from the sale.
• The company expects approximately $250 million in after-tax net proceeds.
• Debt will be reduced using the proceeds.
• Hillenbrand can now focus on its core process and automation equipment business.
• The company retains a 49% ownership stake in Milacron, allowing for potential future returns.

Risks

• The ability to recognize the benefits of the divestiture, including potential synergies and cost savings, is not guaranteed.
• Strategic and operational initiatives implemented by Bain Capital could impact Milacron's performance.
• Failure to satisfy any conditions to the transaction could have adverse effects.
• The announcement or results of the transaction could negatively affect Hillenbrand's stock price.
• Management's attention could be diverted from Hillenbrand's ongoing business operations due to the transaction.

Future Outlook

Hillenbrand expects the transaction to enhance its overall margin profile and enable it to concentrate on growing its core process and automation equipment for the food, pharmaceutical, and polymer end markets; Bain Capital aims to support Milacron's growth and capture opportunities in emerging technology.

Management Comments

• Kim Ryan, President and Chief Executive Officer of Hillenbrand, stated that the transaction reflects the continued transformation of Hillenbrand's portfolio mix as a pure-play industrial company.
• Kim Ryan believes the transaction will deliver value to Hillenbrand and its shareholders by enhancing the company's overall margin profile.
• Matt Evans, a Partner at Bain Capital, expressed excitement about building on Milacron's strong legacy and leadership position.

Industry Context

This announcement reflects a trend of companies streamlining their portfolios to focus on core competencies and higher-growth areas; private equity firms like Bain Capital are actively investing in industrial businesses, seeking to drive growth through operational improvements and strategic investments.

Comparison to Industry Standards

• Comparable companies that have undergone similar divestitures include divisions of larger conglomerates being sold to private equity firms for operational improvements.
• The valuation of the Milacron business can be compared to other injection molding and extrusion businesses acquired by private equity firms, considering factors like revenue multiples and EBITDA multiples.
• The use of proceeds to reduce debt is a common strategy in such transactions, aiming to improve the company's financial flexibility and reduce interest expenses.

Stakeholder Impact

• Shareholders may benefit from the increased focus on core businesses and debt reduction.
• Employees of Milacron will now be part of a Bain Capital-owned company, which may bring changes in strategy and operations.
• Customers of Milacron can expect continued service and potential enhancements under Bain Capital's ownership.
• Suppliers to Milacron will likely see a continuation of business relationships under the new ownership.

Key Dates

Keywords

Milacron, Hillenbrand, Bain Capital, injection molding, extrusion, divestiture, sale, debt reduction, portfolio, industrial